focus -WSS

focus

author：knowledge 2025-09-29 01:08:14 - browse：88172

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： In diabetes hearing, Sanders takes on a new foe: food makers

hotspot

WSS

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Risky weight loss products often used by teens globally, per study

GSK to buy asthma

Pharma patents targeted by Biden in move to slash drug prices

Designating disabled people as health disparity population is crucial

What PEPFAR has meant on the ground in Ukraine

hotspot

focus

hotspot

Guidelines to prevent youth baseball injuries need more muscle

FDA approves world's first CRISPR

Affirmative action in medical school literally saved lives

Designating disabled people as health disparity population is crucial

United colonoscopy coverage change 'may cost lives,' doctors say

Why sickle cell disease is getting the first CRISPR treatment

Novavax promises a turnaround & Lilly roils the obesity market

What PEPFAR has meant on the ground in Ukraine

Medicare details structure of new drug price negotiation program

Risky weight loss products often used by teens globally, per study

hotspot

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Heart disease and mental health: A look at cardiac psychology

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Why sickle cell disease is getting the first CRISPR treatment

Wikipedia

hotspot

knowledge

hotspot